Dexmedetomidine and Neuroprotection in Children Undergoing General Anesthesia

Seoul National University Hospital60 enrolled

Overview

Neuroapoptosis is induced by the administration of anesthetic agents to the young brain. Recent studies showed that the a2-adrenoceptor agonist, dexmedetomidine plays a trophic role during development and is neuroprotective in several settings of neuronal injury in animals. We hypothesized that neuroprotective effect of dexmedetomidine would be associated with evidence of brain injury detected by elevation of plasma concentration of glial fibrillary acid protein in children undergoing general anesthesia.

GFAP measure

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

DIAGNOSTIC

Masking

QUADRUPLE

Enrollment

Conditions

Dexmedetomidine

Interventions

Dexmedetomidine HydrochlorideDRUG

dexmedetomidine 1mcg/kg loading and 0.5mcg/kg/hr continuous infusion during surgery

controlOTHER

0.9% normal saline continuous infusion

Eligibility

Sex: ALLMin age: 1 MonthMax age: 3 Years

Medical Language ↔ Plain English

Inclusion Criteria: * children undergoing general anesthesia longer than 3 hours Exclusion Criteria: * past history of anesthesia * cardiopulmonary bypass * preexisting neurocognitive dysfunction * abnormalities of liver profile (aspartate transaminase \> 40 unit/L, alanine aminotransferase \> 40 unit/L)

Locations (1)

SNUH

Seoul, Jongro Gu, South Korea

Outcomes

Primary Outcomes

Glial fibrillary acid protein

plasma was collected at the given specific time

Time frame: change from baseline glial fibrillary acid protein at 3 hours after the anesthetic induction

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.